Drug intelligence / Profile preview

CTI-108

Development stage: Preclinical
Lead developer: Cellics Therapeutics

Overview

CTI-108 is a preclinical biologic drug candidate being developed by Cellics Therapeutics for inflammatory bowel disease and related digestive system inflammatory disorders. Publicly available sources identify it as a cytokine inhibitor, but do not provide sufficient detail to determine the exact molecular format, cytokine target, or binding mechanism. Based on the limited available information, CTI-108 appears to be an investigational anti-inflammatory immunology program rather than an approved medicine, and its precise mechanism of action remains undisclosed.

Beyond the preview

Go deeper on CTI-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTI-108.

Explore the full profile